Terapeutické monitorovanie infliximabu pri nešpecifických zápalových ochoreniach čreva
Authors:
Y. Jalali; A. Krajcovicova; T. Hlavatý
Authors‘ workplace:
IBD Center, Subdepartment of Gastroenterology and Hepatology, 5th Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital Bratislava, Slovak Republic
Published in:
Gastroent Hepatol 2018; 72(1): 41-46
Category:
IBD: Review Article
doi:
https://doi.org/10.14735/amgh201841
Overview
Antagonisti tumor nekrotizujúceho faktoru α sa v súčasnosti bežne používajú v liečbe stredne ťažkej až ťažkej formy Crohnovej choroby a ulceróznej kolitídy. Približne 50 % pacientov s nešpecifickými zápalovými ochoreniami čreva, ktorí v úvode profitovali z liečby antagonistami tumor nekrotizujúceho faktoru, po čase stratí liečebný účinok. Účinnosť liečby je vysoko závislá od farmakokinetiky a farmakodynamiky. Terapeutické monitorovanie liečiva (TDM – therapeutic drug monitoring), ktoré predstavuje meranie hladiny liečiva ako aj protilátok proti liečivu (ADAb – anti-drug antibodies), je novým prístupom optimalizácie liečby a dosiahnutia najnižšieho rizika straty odpovede. V súčasnosti nie je jasné presná terapeutická hladina, ktorá by zodpovedala klinickej odpovedi. Produkcia ADAb môže viesť k poklesu hladín až neutralizácii liečiva s následnou stratou liečebného účinku. Rovnako môžu ADAb prispieť k infúznym reakciám, tromboembolickým príhodám a sérovej chorobe. Predkladaný článok skúma vývoj TDM pri liečbe IBD. Skúma hlavné tvrdenia o TDM ako aj vývoj ich používania v poslednom období, skúma terapeutické rozmedzie, stratu odpovede a opisuje súčasné trendy v klinickej praxi.
Kľúčové slová:
nešpecifické zápalové ochorenia čreva – terapeutické monitorovanie liečiva – protilátky proti liečivu – biologická terapia – terapeutické rozmedzie
Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.
Doručeno:
21. 12. 2017
Přijato:
30. 1. 2018
Sources
1. Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology 2017; 152 (2): 351–361. doi: 10.1053/j.gastro.2016.09.046.
2. Vande Casteele N, Feagan BG, Gils A et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep 2014; 16 (4): 378. doi: 10.1007/s11894-014-0378-0.
3. Vande Casteele N, Herfarth H, Katz J et al. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology 2017; 153 (3): 835–857. doi: 10.1053/j.gastro.2017.07.031.
4. Maser EA, Villela R, Silverberg MS et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol 2006; 4 (10): 1248–1254.
5. Singh N, Rosenthal CJ, Melmed GY et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2014; 20 (10): 1708–1713. doi: 10.1097/MIB.0000000000000137.
6. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 (15): 1098–1104.
7. Vermeire S, Noman M, Van Assche G et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 2007; 56 (9): 1226–1231.
8. Pariente B, de Chambrun GP, Krzysiek R et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 18 (7): 1199–1206. doi: 10.1002/ibd.21 839.
9. Feuerstein JD, Nguyen GC, Kupfer SS et al. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology 2017; 153 (3): 827–834. doi: 10.1053/ j.gastro.2017.07.032.
10. Papamichael K, Vande Casteele N, Ferrante M et al. Therapeutic drug monitoring during induction of anti-tumor necrosis factor therapy in inflammatory bowel disease: defining a therapeutic drug window. Inflamm Bowel Dis 2017; 23 (9): 1510–1515. doi: 10.1097/MIB.0000000000001231.
11. Papamichael K, Gils A, Rutgeerts P et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis 2014; 21 (1): 182–197. doi: 10.1097/MIB.0000000000000202.
12. Sprakes MB, Ford AC, Warren L et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn‘s disease: a large single centre experience. J Crohns Colitis 2012; 6 (2): 143–153. doi: 10.1016/j.crohns.2011.07.011.
13. Papamichael K, Van Stappen T, Vande Casteele N et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2016; 14 (4): 543–549. doi: 10.1016/j.cgh.2015.11. 014.
14. Roblin X, Boschetti G, Duru G et al. Distinct thresholds of infliximab trough level are associated with different therapeutic outcomes in patients with inflammatory bowel disease: a prospective observational study. Inflamm Bowel Dis 2017; 23 (11): 2048–2053. doi: 10.1097/MIB.0000000000001223.
15. Fay S, Ungar B, Paul S et al. The association between drug levels and endoscopic recurrence in postoperative patients with Crohn‘s disease treated with tumor necrosis factor inhibitors. Inflamm Bowel Dis 2017; 23 (11): 1924–1929. doi: 10.1097/MIB.0000000000001220.
16. Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4 (4): 355–366. doi: 10.1016/j.crohns.2010.04.004.
17. Hlavaty T, Krajcovicova A, Letkovsky J et al. Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumor necrosis factor alpha therapy. Bratis Lek Listy 2016; 117 (4): 205–211.
18. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn‘s disease. N Eng J Med 2003; 348 (7): 601–608.
19. Farrell RJ, Alsahli M, Jeen YT et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn‘s disease: a randomized controlled trial. Gastroenterology 2003; 124 (4): 917–924.
20. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2 (7): 542–553.
21. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn‘s disease. N Eng J Med 2010; 362 (15): 1383–1395. doi: 10.1056/NEJMoa0904 492.
22. Feagan BG, McDonald JW, Panaccione R et al. S1051 methotrexate for the prevention of antibodies to infliximab in patients with Crohn‘s disease. Gastroenterology 2010; 138 (5): S167–S168. doi: 10.1016/S0016-5085 (10) 60767-6.
23. Vande Casteele N, Gils A, Singh S et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108 (6): 962–971. doi: 10.1038/ajg.2013.12.
24. Feagan BG, Singh S, Lockton S et al. 565 Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn‘s disease (CD). Gastroenterology 2012; 142 (5): S114. doi: 10.1016/S0016-5085 (12) 60430-2.
25. Martelli L, Olivera P, Roblin X et al. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. J Gastroenterol 2017; 52 (1): 19–25. doi: 10.1007/s00535-016-1266-1.
26. Arias MT, Vande Casteele N, Vermeire S et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13 (3): 531–538. doi: 10.1016/j.cgh.2014.07.055.
27. Seow CH, Newman A, Irwin SP et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59 (1): 49–54. doi: 10.1136/gut.2009.183095.
28. Adedokun OJ, Sandborn WJ, Feagan BG et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 2014; 147 (6): 1296–1307. doi: 10.1053/j.gastro.2014.08.035.
29. Brandse JF, Mathôt RA, van der Kleij D et al. Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2016; 14 (2): 251–258. doi: 10.1016/j.cgh.2015.10.029.
30. Feagan BG, McDonald JW, Panaccione R et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn‘s disease. Gastroenterology 2014; 146 (3): 681–688. doi: 10.1053/j.gastro.2013.11.024.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
![Issue 1](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/a8d790d6b8c272bc4b05aef083453da2.jpeg)
2018 Issue 1
Most read in this issue
- VSL#3 – první vysoce koncentrované probiotikum s mnohočetnými probiotickými kulturami a ověřenou terapeutickou účinností
- Onemocnění gastrointestinálního traktu a choroby ledvin
- Postavení CT kolografie v algoritmu vyšetření tlustého střeva
- Odporúčania Pracovnej skupiny pre IBD Slovenskej gastroenterologickej spoločnosti pre liečbu Crohnovej choroby